ReviewCancer metastasis reviews2024
Epidemiology of nasopharyngeal carcinoma: current insights and future outlook.
Review in Cancer metastasis reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 7 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Primary endoscopic nasopharyngectomy for nasopharyngeal carcinoma: systematic review & meta-analysis.Frontiers in surgery · 2026Pooled it
- Prognostic significance of inflammation-based markers in nasopharyngeal carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic value of sarcopenia in patients with nasopharyngeal carcinoma: a meta-analysis.Annals of medicine · 2025Pooled it
- PD-1/PD-L1 inhibitors for locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis based on randomized controlled trials.BMC cancer · 2025Pooled it
- Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.British journal of cancer · 2025Pooled it
- Quality of life in nasopharyngeal carcinoma survivors: a systematic review and meta-analysis of longitudinal outcomes.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Pooled it
- A Current Perspective of Two of the Most Aggressive Head and Neck Cancers: Pharyngeal and Laryngeal.Current oncology (Toronto, Ont.) · 2025Pooled it
- Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.Signal transduction and targeted therapy · 2026Trial
- Impact of concurrent chemotherapy dose on long-term survival in locally advanced nasopharyngeal carcinoma: a 10-year single-center study.BMC cancer · 2026Trial
- Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors.Cancer immunology, immunotherapy : CII · 2025Trial
- The current role of immunotherapy in treating nasopharyngeal carcinoma.Human vaccines & immunotherapeutics · 2026Review
- Review
- TRIM26 triggers ferroptosis via ZEB1 degradation to suppress nasopharyngeal carcinoma progression.Journal of molecular histology · 2026Article
- Article
- Single-cell transcriptomics and functional validation reveal a TUBB4B-associated malignant epithelial state in nasopharyngeal carcinoma.Journal of translational medicine · 2026Article
- Prognostic Value of Cranial Nerve Invasion in T4-Stage Nasopharyngeal Carcinoma: A Retrospective Cohort Study With a Median Follow-Up of 136 Months.Health science reports · 2026Article
- MiR-138-5p Suppresses Glucose Metabolism to Inhibit the Progression of Nasopharyngeal Carcinoma by Targeting the CENPN/PI3K/Akt/mTOR Signaling.Journal of biochemical and molecular toxicology · 2026Article
- Anti-BNLF2b antibody for accurate diagnosis of nasopharyngeal carcinoma: a prospective comparative study.BMC cancer · 2026Article
- Review
- MicroRNA-23b: Roles, functions and mechanisms in tumor.Genes & diseases · 2026Review
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Nasopharyngeal carcinoma (NPC) is characterised by its remarkable geographical and ethnic distribution. The interplay between genetic susceptibility, environmental exposures, and Epstein-Barr virus (EBV) infections is indicated in the development of NPC. Exposure to tobacco smoking, dietary factors, and inhalants has been associated with the risk of NPC. Genetic association studies have revealed NPC-associated susceptibility loci, including genes involved in immune responses, xenobiotic metabolism, genome maintenance, and cell cycle regulation. EBV exposure timing and strain variation might play a role in its carcinogenicity, although further investigations are required. Other factors including medical history and oral hygiene have been implicated in NPC. Prevention strategies, including primary prevention and secondary prevention through early detection, are vital in reducing mortality and morbidity of NPC. The current review discusses the global and regional distribution of NPC incidences, the risk factors associated with NPC, and the public health implications of these insights. Future investigations should consider international, large-scale prospective studies to elucidate the mechanisms underlying NPC pathogenesis and develop individualized interventions for NPC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.